Lilly’s CoLAB Program: Using Clinical Trial 'Dress Rehearsal' Simulations to Reduce Patient Burden and Improve Protocol Design
Source
Clinical Leader
Link
Clinical Trial Design Is A Two-Way Street
Description of Case Study
Lilly launched a clinical trial simulation, CoLAB, to address a known barrier to clinical trial enrollment: Many eligible people don’t participate because they don’t understand a study’s purpose or find the process too long, complicated, or intensive. Running for more than five years across Lilly’s clinical portfolio, CoLAB convenes patients, caregivers, study coordinators, nurses, and physicians for a daylong “dress rehearsal” of a draft trial protocol, walking through elements like dosing, visit schedules, and sample collection to surface what would and wouldn’t work in practice. Explicit ground rules (e.g., setting aside hierarchy, staying engaged for the full session) keep participant input—not sponsor talking points—at the center of the discussion. The goal is to catch and resolve sources of patient and site burden early enough to shape a simpler, more convenient, more patient-friendly protocol before it is finalized.
Quick Facts Organization name: Eli Lilly and Company |
Product Type(s)
- pharmaceutical/biological product
Stakeholders
- medtech company: internal research and development/clinical affairs teams
- patients and caregivers, patient organizations
- providers (clinicians, hospital/health system administrators)
Methods and Sources of Patient Input
- interviews/focus groups/surveys
- patient-developed solutions
- other: simulation
Impact of Patient Engagement
This example shows how patient engagement can produce trial designs that are more practical, accessible, and aligned with patient needs, improving enrollment and retention. Engaging patients early in research and development helps sponsors build trust, identify and address participation barriers, avoid costly missteps, and reduce overall burden.
Reported areas of impact include:
- More patient-centered protocol design: Input from patients, caregivers, and site staff helped identify elements—such as visit length, sample collection, and dosing logistics—that could be simplified or removed before finalization.
- Reduced procedural and logistical burden: Simulation feedback led to changes such as switching from blister packs to bottles, reducing or eliminating invasive procedures (e.g., biopsies, endoscopies), and arranging overnight stays for patients traveling long distances.
- Stronger relationships and trust: Participants felt heard and saw their feedback reflected, with sponsor teams prioritizing listening over directing.
- Operational efficiencies for sponsors: Improvements included more aligned study teams, less protocol rework, lower costs, and lessons that could be applied across trials.
Lessons Learned
By deploying CoLAB across multiple studies, Lilly has found that each simulation offers unique opportunities to reduce patient burden by adapting trial procedures and materials to better meet patient needs and capabilities. Incorporating patient perspectives can lead to meaningful improvements, such as simplifying packaging, reducing invasive procedures, and eliminating unnecessary study requirements. Lessons from one study can also be leveraged to improve future study design. Additional lessons include:
- Create a low-hierarchy environment for candid input: Lilly found it important to set explicit ground rules for simulations (e.g., “leave your title at the door,” stay engaged for the full day, think big) so that patient and site input—not internal hierarchy—drove the discussion.
- Sponsor teams should listen more than they direct: Participants noted that Lilly staff from across departments (business, design, medical, community liaisons) attended primarily to listen, with patient and site input, not sponsor talking points, intentionally kept as the focus of the day.
- Engage a broad set of voices, not just patients: Including study coordinators, nurses, and physicians alongside patients and caregivers helped identify burdens from multiple vantage points; for example, site staff could flag visit structures or procedures that would be logistically difficult to execute, not just difficult to undergo.
- Earlier engagement could unlock more impact: Lilly identified an opportunity to apply the same simulation-based approach even earlier in clinical development—to help shape study design itself rather than only refining a near-final protocol—and to broaden the diversity of external experts involved (e.g., on patient populations, objectives, and comparator therapies).